scispace - formally typeset
Y

Yoshinobu Koyama

Publications -  3
Citations -  215

Yoshinobu Koyama is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 146 citations.

Papers
More filters
Journal ArticleDOI

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, +90 more
- 08 Dec 2018 - 
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI

Treatment resistance of rheumatoid arthritis relates to infection of periodontal pathogenic bacteria: a case–control cross-sectional study

TL;DR: In this article , the authors investigated the relationship between periodontal pathogenic bacterial infections and smoking in patients with rheumatoid arthritis or polymyalgia rheumatica (PMR), and they found an association between the elevated antibody titer against Pg and the degree of ACPA value.
Journal ArticleDOI

Pos0311 il-6 inhibitors and jak inhibitors: which of these drugs, inhibiting a common pathway, has an advantage in preventing bone destruction in ra?

TL;DR: Koyama et al. as discussed by the authors examined changes in peripheral blood gene expression after IL-6i or JAKi treatment, which inhibit common pathways, and to estimate their respective effects on the bone immune system.